UCB S.A. (UCBJF)
UCB S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Brussels, BU, BE. The stock last traded at $235.66, down 3.37% on the session, giving a market capitalisation of $44.86B. On trailing twelve-month figures it carries a trailing P/E of 18.56, a net margin of 25.7%. Its beta of 0.20 implies it has historically moved less than the broad market.
UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters. Neupro is available for patients with Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Additionally, the company offers Evenity to treat osteoporosis in postmenopausal women, and BIMZELX, approved for conditions like psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also part of its offerings for systemic lupus erythematosus. In its robust development pipeline, UCB is advancing several investigational medicines, including rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged stereotypical seizures; Bepranemab targeting Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its core pharmaceutical activities, UCB also provides contract manufacturing services. The company has forged strategic collaboration agreements with major industry players such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. With its headquarters in Brussels, Belgium, and established in 1925, UCB maintains a significant international presence, operating across the United States, Japan, Germany, China, Belgium, and other key European markets including France, Italy, Spain, the United Kingdom, and Ireland.
UCB S.A. is most often compared with the following Healthcare names: